Cargando…

Metabolomic Analyses to Identify Candidate Biomarkers of Cystinosis

Cystinosis is a rare, devastating hereditary disease secondary to recessive CTNS gene mutations. The most commonly used diagnostic method is confirmation of an elevated leukocyte cystine level; however, this method is expensive and difficult to perform. This study aimed to identify candidate biomark...

Descripción completa

Detalles Bibliográficos
Autores principales: Nemutlu, Emirhan, Ozaltin, Fatih, Yabanoglu-Ciftci, Samiye, Gulhan, Bora, Eylem, Cemil Can, Baysal, İpek, Gök-Topak, Elif Damla, Ulubayram, Kezban, Sezerman, Osman Ugur, Ucar, Gulberk, Kır, Sedef, Topaloglu, Rezan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916752/
https://www.ncbi.nlm.nih.gov/pubmed/36768921
http://dx.doi.org/10.3390/ijms24032603
_version_ 1784886202117128192
author Nemutlu, Emirhan
Ozaltin, Fatih
Yabanoglu-Ciftci, Samiye
Gulhan, Bora
Eylem, Cemil Can
Baysal, İpek
Gök-Topak, Elif Damla
Ulubayram, Kezban
Sezerman, Osman Ugur
Ucar, Gulberk
Kır, Sedef
Topaloglu, Rezan
author_facet Nemutlu, Emirhan
Ozaltin, Fatih
Yabanoglu-Ciftci, Samiye
Gulhan, Bora
Eylem, Cemil Can
Baysal, İpek
Gök-Topak, Elif Damla
Ulubayram, Kezban
Sezerman, Osman Ugur
Ucar, Gulberk
Kır, Sedef
Topaloglu, Rezan
author_sort Nemutlu, Emirhan
collection PubMed
description Cystinosis is a rare, devastating hereditary disease secondary to recessive CTNS gene mutations. The most commonly used diagnostic method is confirmation of an elevated leukocyte cystine level; however, this method is expensive and difficult to perform. This study aimed to identify candidate biomarkers for the diagnosis and follow-up of cystinosis based on multiomics studies. The study included three groups: newly-diagnosed cystinosis patients (patient group, n = 14); cystinosis patients under treatment (treatment group, n = 19); and healthy controls (control group, n = 30). Plasma metabolomics analysis identified 10 metabolites as candidate biomarkers that differed between the patient and control groups [L-serine, taurine, lyxose, 4-trimethylammoniobutanoic acid, orotic acid, glutathione, PE(O-18:1(9Z)/0:0), 2-hydroxyphenyl acetic acid, acetyl-N-formil-5-metoxikinuramine, 3-indoxyl sulphate]. As compared to the healthy control group, in the treatment group, hypotaurine, phosphatidylethanolamine, N-acetyl-d-mannosamine, 3-indolacetic acid, p-cresol, phenylethylamine, 5-aminovaleric acid, glycine, creatinine, and saccharic acid levels were significantly higher, and the metabolites quinic acid, capric acid, lenticin, xanthotoxin, glucose-6-phosphate, taurine, uric acid, glyceric acid, alpha-D-glucosamine phosphate, and serine levels were significantly lower. Urinary metabolomic analysis clearly differentiated the patient group from the control group by means of higher allo-inositol, talose, glucose, 2-hydroxybutiric acid, cystine, pyruvic acid, valine, and phenylalanine levels, and lower metabolite (N-acetyl-L-glutamic acid, 3-aminopropionitrile, ribitol, hydroquinone, glucuronic acid, 3-phosphoglycerate, xanthine, creatinine, and 5-aminovaleric acid) levels in the patient group. Urine metabolites were also found to be significantly different in the treatment group than in the control group. Thus, this study identified candidate biomarkers that could be used for the diagnosis and follow-up of cystinosis.
format Online
Article
Text
id pubmed-9916752
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99167522023-02-11 Metabolomic Analyses to Identify Candidate Biomarkers of Cystinosis Nemutlu, Emirhan Ozaltin, Fatih Yabanoglu-Ciftci, Samiye Gulhan, Bora Eylem, Cemil Can Baysal, İpek Gök-Topak, Elif Damla Ulubayram, Kezban Sezerman, Osman Ugur Ucar, Gulberk Kır, Sedef Topaloglu, Rezan Int J Mol Sci Article Cystinosis is a rare, devastating hereditary disease secondary to recessive CTNS gene mutations. The most commonly used diagnostic method is confirmation of an elevated leukocyte cystine level; however, this method is expensive and difficult to perform. This study aimed to identify candidate biomarkers for the diagnosis and follow-up of cystinosis based on multiomics studies. The study included three groups: newly-diagnosed cystinosis patients (patient group, n = 14); cystinosis patients under treatment (treatment group, n = 19); and healthy controls (control group, n = 30). Plasma metabolomics analysis identified 10 metabolites as candidate biomarkers that differed between the patient and control groups [L-serine, taurine, lyxose, 4-trimethylammoniobutanoic acid, orotic acid, glutathione, PE(O-18:1(9Z)/0:0), 2-hydroxyphenyl acetic acid, acetyl-N-formil-5-metoxikinuramine, 3-indoxyl sulphate]. As compared to the healthy control group, in the treatment group, hypotaurine, phosphatidylethanolamine, N-acetyl-d-mannosamine, 3-indolacetic acid, p-cresol, phenylethylamine, 5-aminovaleric acid, glycine, creatinine, and saccharic acid levels were significantly higher, and the metabolites quinic acid, capric acid, lenticin, xanthotoxin, glucose-6-phosphate, taurine, uric acid, glyceric acid, alpha-D-glucosamine phosphate, and serine levels were significantly lower. Urinary metabolomic analysis clearly differentiated the patient group from the control group by means of higher allo-inositol, talose, glucose, 2-hydroxybutiric acid, cystine, pyruvic acid, valine, and phenylalanine levels, and lower metabolite (N-acetyl-L-glutamic acid, 3-aminopropionitrile, ribitol, hydroquinone, glucuronic acid, 3-phosphoglycerate, xanthine, creatinine, and 5-aminovaleric acid) levels in the patient group. Urine metabolites were also found to be significantly different in the treatment group than in the control group. Thus, this study identified candidate biomarkers that could be used for the diagnosis and follow-up of cystinosis. MDPI 2023-01-30 /pmc/articles/PMC9916752/ /pubmed/36768921 http://dx.doi.org/10.3390/ijms24032603 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Nemutlu, Emirhan
Ozaltin, Fatih
Yabanoglu-Ciftci, Samiye
Gulhan, Bora
Eylem, Cemil Can
Baysal, İpek
Gök-Topak, Elif Damla
Ulubayram, Kezban
Sezerman, Osman Ugur
Ucar, Gulberk
Kır, Sedef
Topaloglu, Rezan
Metabolomic Analyses to Identify Candidate Biomarkers of Cystinosis
title Metabolomic Analyses to Identify Candidate Biomarkers of Cystinosis
title_full Metabolomic Analyses to Identify Candidate Biomarkers of Cystinosis
title_fullStr Metabolomic Analyses to Identify Candidate Biomarkers of Cystinosis
title_full_unstemmed Metabolomic Analyses to Identify Candidate Biomarkers of Cystinosis
title_short Metabolomic Analyses to Identify Candidate Biomarkers of Cystinosis
title_sort metabolomic analyses to identify candidate biomarkers of cystinosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916752/
https://www.ncbi.nlm.nih.gov/pubmed/36768921
http://dx.doi.org/10.3390/ijms24032603
work_keys_str_mv AT nemutluemirhan metabolomicanalysestoidentifycandidatebiomarkersofcystinosis
AT ozaltinfatih metabolomicanalysestoidentifycandidatebiomarkersofcystinosis
AT yabanogluciftcisamiye metabolomicanalysestoidentifycandidatebiomarkersofcystinosis
AT gulhanbora metabolomicanalysestoidentifycandidatebiomarkersofcystinosis
AT eylemcemilcan metabolomicanalysestoidentifycandidatebiomarkersofcystinosis
AT baysalipek metabolomicanalysestoidentifycandidatebiomarkersofcystinosis
AT goktopakelifdamla metabolomicanalysestoidentifycandidatebiomarkersofcystinosis
AT ulubayramkezban metabolomicanalysestoidentifycandidatebiomarkersofcystinosis
AT sezermanosmanugur metabolomicanalysestoidentifycandidatebiomarkersofcystinosis
AT ucargulberk metabolomicanalysestoidentifycandidatebiomarkersofcystinosis
AT kırsedef metabolomicanalysestoidentifycandidatebiomarkersofcystinosis
AT topaloglurezan metabolomicanalysestoidentifycandidatebiomarkersofcystinosis